ERBB2 and breast cancer: (Nonobese diabetic) NOD/(severe combined immunodeficient) SCID mice bearing human breast cancer xenografts overexpressing HER2 demonstrated that tumor growth inhibition was significantly higher when compared to mice injected with 177Lu@AuNPs or untreated mice, over a 16-day period.